Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
JANX 
Janux Therapeutics Inc (JANX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/07/2026: JANX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $64.29
1 Year Target Price $64.29
| 11 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 29.1% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 01/07/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 808.39M USD | Price to earnings Ratio - | 1Y Target Price 64.29 |
Price to earnings Ratio - | 1Y Target Price 64.29 | ||
Volume (30-day avg) 13 | Beta 2.88 | 52 Weeks Range 13.26 - 50.89 | Updated Date 01/7/2026 |
52 Weeks Range 13.26 - 50.89 | Updated Date 01/7/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.67 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -352.51% |
Management Effectiveness
Return on Assets (TTM) -10.49% | Return on Equity (TTM) -12.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -139902132 | Price to Sales(TTM) 80.84 |
Enterprise Value -139902132 | Price to Sales(TTM) 80.84 | ||
Enterprise Value to Revenue 972.59 | Enterprise Value to EBITDA -33.8 | Shares Outstanding 60147807 | Shares Floating 44987552 |
Shares Outstanding 60147807 | Shares Floating 44987552 | ||
Percent Insiders 6.91 | Percent Institutions 110.15 |
Upturn AI SWOT
Janux Therapeutics Inc
Company Overview
History and Background
Janux Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. Founded in 2019, the company is dedicated to creating a new class of tumor-activated therapeutics. Key milestones include the initiation of clinical trials for its lead drug candidates.
Core Business Areas
- Oncology Therapeutics: Janux is developing targeted therapies designed to activate the immune system within the tumor microenvironment. Their approach aims to overcome resistance to existing immunotherapies and address unmet needs in cancer treatment.
Leadership and Structure
Janux Therapeutics Inc. is led by a management team with extensive experience in drug development and the biotechnology industry. The organizational structure is typical for a clinical-stage biopharmaceutical company, emphasizing R&D, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- JANX-007 (LAURNT): A novel tumor-activated, conditionally controlled, biparatopic T-cell engager. This drug is designed to be selectively activated within the tumor microenvironment, minimizing systemic toxicity. Competitors in the T-cell engager space include Amgen (Blincyto), Genmab (Tivdak), and Pfizer (Elrexfio).
- JANX-008 (LAURNT-TRAP): Another conditionally controlled, biparatopic T-cell engager targeting solid tumors. It aims to overcome the limitations of non-selective T-cell engagers. Competitors are similar to those for JANX-007.
Market Dynamics
Industry Overview
The oncology therapeutics market is highly competitive and rapidly evolving, driven by advancements in immunotherapy, targeted therapies, and personalized medicine. The demand for novel treatments with improved efficacy and reduced toxicity is significant.
Positioning
Janux Therapeutics Inc. is positioning itself as a leader in developing a new generation of tumor-activated therapeutics. Their unique approach to conditional activation aims to provide a significant competitive advantage by enhancing safety and efficacy.
Total Addressable Market (TAM)
The TAM for oncology therapeutics is in the hundreds of billions of dollars globally. Janux Therapeutics Inc. is positioned to capture a segment of this market by addressing specific cancer types and patient populations with unmet needs. Their TAM will expand as their drug candidates progress through clinical development and receive regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel drug development platform with a focus on tumor activation.
- Experienced management team with a strong scientific background.
- Potential to overcome limitations of existing immunotherapies.
Weaknesses
- Clinical-stage company with no approved products.
- Reliance on successful clinical trial outcomes.
- Limited financial resources compared to larger pharmaceutical companies.
Opportunities
- Significant unmet needs in various cancer indications.
- Potential for strategic partnerships and collaborations.
- Advancements in understanding the tumor microenvironment.
Threats
- High failure rate in clinical drug development.
- Intense competition from established and emerging biopharmaceutical companies.
- Regulatory hurdles and lengthy approval processes.
Competitors and Market Share
Key Competitors
- Amgen (AMGN)
- Genmab (GMAB)
- Pfizer (PFE)
Competitive Landscape
Janux's competitive advantages lie in its novel tumor-activated platform, which could offer improved safety and efficacy profiles compared to existing T-cell engagers. However, it faces significant disadvantages in terms of market presence, financial resources, and established commercial infrastructure compared to larger, established pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily in the expansion of its R&D pipeline and the advancement of its drug candidates into clinical trials. The company has also focused on building its scientific team and infrastructure.
Future Projections: Future growth is contingent on the successful clinical development and potential commercialization of its drug candidates. Analyst projections, if available, would focus on potential market penetration and revenue generation post-approval.
Recent Initiatives: Recent initiatives likely include the advancement of their lead drug candidates (JANX-007 and JANX-008) through clinical trials, potential strategic collaborations, and ongoing efforts to secure funding.
Summary
Janux Therapeutics Inc. is a promising clinical-stage biopharmaceutical company with a novel approach to cancer therapy. Its tumor-activated drug platform offers potential advantages in safety and efficacy. However, the company faces significant risks inherent in drug development, including clinical trial failures and intense competition. Successful execution of its clinical strategy and securing adequate funding are crucial for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (e.g., SEC filings)
- Financial news outlets
- Industry analysis reports
- Biotechnology databases
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. The data presented is based on publicly available information and is subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Janux Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-06-11 | President, CEO & Director Dr. David Alan Campbell Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 109 | Website https://www.januxrx.com |
Full time employees 109 | Website https://www.januxrx.com | ||
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.